Robert F. Apple, Chief Operating Officer
InKine Pharmaceutical Company, Inc.

Donald C. Weinberger
Wolfe Axelrod Weinberger Assoc. LLC
212-370-4500, 212-370-4505 fax
[email protected]



BLUE BELL, PA October 2, 2003 -- InKine Pharmaceutical Company, Inc. (Nasdaq: INKP) today announced that a review article published today in the New England Journal of Medicine (NEJM) listed Visicol ® as a medication that is commonly used to treat constipation.   The article was written by Anthony Lembo, M.D. from the Gastroenterology Division, Beth Israel Deaconess Medical Center in Boston and Michael Camilleri, M.D. from the Gastroenterology Division, Mayo Clinic in Rochester, Minnesota.   The article, entitled "Chronic Constipation," is in the NEJM's "Current Concepts" series of reviews of important medical topics.   The article describes the pathophysiology, evaluation, and management of chronic constipation, and includes Visicol ® in a list of drugs commonly used to treat this condition.  

Positive results from a post marketing study using Visicol ® tablets as a laxative were recently announced.   The study, which was performed in 31 adult, healthy volunteers, was a controlled, randomized open label trial that compared the safety and laxative effects of Visicol ® tablets to MiraLax ® , the leading marketed prescription laxative.   The study results, which will be presented at the Annual Scientific Meeting of the American College of Gastroenterology, held in Baltimore from October 10 to 15, show a consistent statistically significant pattern of greater and more prompt laxative effects for Visicol ® over MiraLax ® .

A multicenter, randomized, 28-day, dose-finding study of Visicol ® in patients with idiopathic constipation or constipation-predominant irritable bowel syndrome (IBS) is currently underway in the US.

"Constipation, which affects over four million Americans, represents a major expansion of the medical utility of Visicol ® ," said Martin Rose, M.D., J.D.,   InKine's Executive Vice President for Research and Development.   "We are moving forward as rapidly as possible with studies to add a constipation indication to the approved labeling for Visicol ® ."

Visicol ® , an oral tablet containing sodium phosphate monobasic monohydrate, USP and sodium phosphate dibasic anhydrous, USP, is currently indicated for cleansing of the bowel as a preparation for colonoscopy, in adults 18 years of age or older.  

About InKine Pharmaceutical
InKine Pharmaceutical Company, Inc. is a publicly traded biopharmaceutical company focused on the diagnosis and treatment of cancer and autoimmune diseases. The Company's development strategy is to acquire late-stage drug candidates with short time lines to commercialization. The Company's first product, Visicol™ is the first and only tablet purgative preparation indicated for bowel cleansing prior to colonoscopy. InKine's second product, IBStat™, is a novel oral hysocyamine spray for the treatment of Irritable Bowel Syndrome (IBS) and spasm of the colon. Additionally, the Company is developing other clinical compounds such as Colirest™, which is in clinical trials for the treatment of Crohn's disease and completed Phase II trials for the treatment of ulcerative colitis. For further information, please visit InKine on their web site http://www.inkine.com.

In addition to historical facts or statement of current condition, this press release may contain forward-looking statements. Forward-looking statements provide InKine's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential pharmaceutical products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, sales and earnings projections, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. InKine's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties such as those set forth in its reports on Form 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, InKine does not intend (and it is not obligated) to update publicly any forward-looking statements. This discussion is permitted by the Private Securities Litigation Reform Act of 1995.